ELUT
Elutia Inc.
There isn't enough reported data to score ELUT yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ELUT Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Unavailable |
ELUT's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ELUT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 0.8x | $0.94 | +7.2% |
| Current | 0.8x | $0.88 | — |
| Fair | 1x | $1.18 | +34% |
| Expensive | 1.2x | $1.43 | +62% |
Historical ranges are pointers, not guarantees.
ELUT's PE is 0.8x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ELUT Forward outlook
There aren't enough analyst estimates for ELUT to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ELUT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $1.15 | +$2.07 |
| Q2 2026 | $1.00 | +$2.06 |
| Q1 2026 | $0.91 | +$2.84 |
| Q4 2025 | $0.87 | +$3.34 |
| Q3 2025 | -$0.92 | +$1.65 |
| Q2 2025 | -$1.06 | +$1.75 |
| Q1 2025 | -$1.93 | +$0.40 |
| Q4 2024 | -$2.47 | -$0.40 |
ELUT has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ELUT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1M | -66% |
| Q2 2026 | $2.4M | -61% |
| Q1 2026 | $3.1M | -48% |
| Q4 2025 | $3.3M | -40% |
| Q3 2025 | $3.3M | -44% |
| Q2 2025 | $6.3M | -0.4% |
| Q1 2025 | $6M | -9.9% |
| Q4 2024 | $5.5M | -6.9% |
ELUT's revenue has slid since its 2023 peak: $1M last quarter, down 66% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -607% | -450 points |
| Q2 2026 | -328% | -170 points |
| Q1 2026 | -204% | -73 points |
| Q4 2025 | -201% | -46 points |
| Q3 2025 | -157% | +16 points |
| Q2 2025 | -158% | -22 points |
| Q1 2025 | -131% | -4.7 points |
| Q4 2024 | -154% | -9.4 points |
ELUT's operating margin was −607% last quarter, down 450 points from the same quarter a year ago, near the bottom of its range since 2020.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ELUT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over ELUT on profitability, with a higher operating margin.
ELUT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$8.2M | -$4.7M |
| Q2 2026 | -$8.6M | -$210K |
| Q1 2026 | -$8.3M | +$869K |
| Q4 2025 | -$25.7M | -$13.3M |
| Q3 2025 | -$3.5M | +$457K |
| Q2 2025 | -$8.3M | -$4M |
| Q1 2025 | -$9.2M | -$6.5M |
| Q4 2024 | -$12.4M | -$3.3M |
ELUT has burned cash in almost every quarter: −$51M over the past year, against −$33M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ELUT on cash generation, producing positive trailing cash flow while its opponent burns cash.
ELUT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.5% | +3.3M shares |
| 1 year | +1.2% | +581K shares |
| 3 years | +179% | +30.5M shares |
| 5 years | +364% | +37.3M shares |
ELUT has 48M diluted shares, up 1.2% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ELUT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ELUT Net Leverage
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ELUT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.8 | Neutral |
| Stochastic | 47.7 | Neutral |
ELUT's weekly RSI is 48 (neutral) and its Stochastic is 48 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ELUT PE vs Healthcare Sector
| Metric | ELUT | Sector median | Relative |
|---|---|---|---|
| PE | 0.8x | 26x | 97% below |
| PE % | 3 | 33 | 30 pts below |
ELUT is trading at 0.8x earnings, a 97% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ELUT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.83 | 6% above |
| 20 week MA | $0.87 | 1.1% above |
| 50 week MA | $0.93 | 5.4% below |
| 100 week MA | $1.53 | 42% below |
| 200 week MA | $2.24 | 61% below |
ELUT has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ELUT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.5 | $12.6 | -7.2% |
| 2021 | $12.6 | $6.67 | -47% |
| 2022 | $6.67 | $4.10 | -39% |
| 2023 | $4.10 | $2.16 | -47% |
| 2024 | $2.16 | $3.94 | +82% |
| 2025 | $3.94 | $0.54 | -86% |
| 2026 YTD | $0.54 | $0.88 | +63% |
ELUT has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.